Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Biofrontera Inc. (BFRI)

Biofrontera Ameluz wins FDA approval for superficial basal cell carcinoma

Positive Impact 3 of 5 product/contract Written later

The FDA approved Biofrontera's supplemental New Drug Application for Ameluz with the BF-RhodoLED lamp for superficial basal cell carcinoma in adults. The company says this makes Ameluz the first and only photodynamic therapy approved by the FDA for a skin cancer, and that it expands the addressable market. The filing gives no revenue, sales or financial impact figures.

Key points

  • FDA approval announced September 14, 2026 for Ameluz with BF-RhodoLED lamp for superficial basal cell carcinoma in adults
  • Phase 3 trial in 187 adults: 66% (95 of 145) of Ameluz PDT subjects achieved the primary endpoint versus 5% (2 of 42) on placebo-PDT
  • Company plans an official launch of the new indication late in Q4 2026 through Q1 2027, using its existing commercial organization and lamp base

The filing

CompanyBiofrontera Inc. (BFRI)
Form8-K, current report
Filed with the SECSep 14, 2026, 9:29 AM ET
Accession number0001493152-26-042508

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.